|
|
| | 3,6,9,12-Tetraoxatetradecanoic acid, 14-hydroxy- Basic information |
| Product Name: | 3,6,9,12-Tetraoxatetradecanoic acid, 14-hydroxy- | | Synonyms: | 3,6,9,12-Tetraoxatetradecanoic acid, 14-hydroxy-;HO-PEG4-CH2COOH;2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]aceticacid;Hydroxy-PEG4-CH2CO2H;Hydroxy-PEG4-CH2CO2H, sodium salt;14-hydroxy-3,6,9,12-tetraoxatetradecanoic acid;HO-PEG4-CH2COOH/3,6,9,12-Tetraoxatetradecanoic acid, 14-hydroxy- | | CAS: | 70678-95-4 | | MF: | C10H20O7 | | MW: | 252.26 | | EINECS: | | | Product Categories: | PROTAC LINKER | | Mol File: | 70678-95-4.mol |  |
| | 3,6,9,12-Tetraoxatetradecanoic acid, 14-hydroxy- Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | 3,6,9,12-Tetraoxatetradecanoic acid, 14-hydroxy- Usage And Synthesis |
| Description | Hydroxy-PEG4-CH2CO2H, sodium salt, is a PEG derivative containing a hydroxyl group with a terminal carboxylic acid. The terminal carboxylic acid can be reacted with primary amine groups in the presence of activators (e.g. EDC, or DCC) to form a stable amide bond. The hydrophilic PEG spacer increases solubility in aqueous media. The hydroxyl group enables further derivatization or replacement with other reactive functional groups. | | Uses | Hydroxy-PEG4-CH2COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. | | IC 50 | PEGs | | References | [1] An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562. DOI:10.1016/j.ebiom.2018.09.005 |
| | 3,6,9,12-Tetraoxatetradecanoic acid, 14-hydroxy- Preparation Products And Raw materials |
|